Key Points
- Beth Hecht sold 16,667 shares of Xeris Biopharma on January 2 at an average price of $7.43 for about $123,836, leaving her with 1,308,103 shares (a 1.26% reduction, valued ~ $9.72M).
- This sale continues a recent pattern—Hecht also sold 16,667 shares on December 1 (at $7.01) and November 11 (at $7.40), indicating multiple insider disposals over the past months.
- Xeris (NASDAQ:XERS) trades near $7.09 with a 1‑year range of $3.14–$10.08 and a $1.18B market cap; analysts' consensus is a Moderate Buy with an average price target of $9.50 and mixed ratings from buy to sell.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of Xeris Biopharma stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $7.43, for a total value of $123,835.81. Following the completion of the transaction, the insider owned 1,308,103 shares of the company's stock, valued at approximately $9,719,205.29. This trade represents a 1.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Beth Hecht also recently made the following trade(s):
- On Monday, December 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $7.01, for a total value of $116,835.67.
- On Tuesday, November 11th, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $7.40, for a total value of $123,335.80.
Xeris Biopharma Stock Performance
Shares of XERS opened at $7.09 on Tuesday. Xeris Biopharma Holdings, Inc. has a 1 year low of $3.14 and a 1 year high of $10.08. The stock has a market capitalization of $1.18 billion, a PE ratio of -70.89 and a beta of 0.50. The stock has a 50-day simple moving average of $7.52 and a 200-day simple moving average of $7.12.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported $0.00 earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.01). The company had revenue of $74.38 million for the quarter, compared to analysts' expectations of $74.19 million. Analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.
Analysts Set New Price Targets
A number of research firms have weighed in on XERS. Barclays initiated coverage on Xeris Biopharma in a research note on Monday, December 8th. They issued an "overweight" rating and a $9.00 price target on the stock. Zacks Research lowered Xeris Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, October 30th. Weiss Ratings restated a "sell (d-)" rating on shares of Xeris Biopharma in a research note on Wednesday, October 8th. Oppenheimer reiterated an "outperform" rating and issued a $18.00 price target on shares of Xeris Biopharma in a research note on Friday, November 7th. Finally, Wall Street Zen cut shares of Xeris Biopharma from a "strong-buy" rating to a "hold" rating in a report on Saturday, November 8th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $9.50.
Read Our Latest Analysis on XERS
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. AlphaQuest LLC purchased a new stake in Xeris Biopharma in the third quarter valued at approximately $35,000. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Xeris Biopharma by 179.3% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company's stock valued at $63,000 after acquiring an additional 5,000 shares during the period. State of Alaska Department of Revenue purchased a new stake in Xeris Biopharma in the 3rd quarter valued at $68,000. Mercer Global Advisors Inc. ADV acquired a new stake in Xeris Biopharma during the 3rd quarter worth $85,000. Finally, Brooklyn Investment Group purchased a new position in Xeris Biopharma during the 3rd quarter worth $99,000. Hedge funds and other institutional investors own 42.75% of the company's stock.
Xeris Biopharma Company Profile
(
Get Free Report)
Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company's proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.
The company's flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
